A reminder. EMA is going just to issue an opinion to MHRA. There is NO decision from EMA, therefore it is not subject to the Committee schedule.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
AXN Rising demand, China's 'tech war' bans leaves this germanium explorer with significant investment potential
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025